Brief: XBIOTECH ENROLLS FIRST PATIENT IN STUDY EVALUATING MABP1 IN WITH ONIVYDE
18/10/2017 15:43
Oct 18 (Reuters) - Xbiotech Inc XBIT.O :
* ENROLS FIRST PATIENT IN STUDY EVALUATING MABP1 IN
COMBINATION WITH ONIVYDE & 5-FLUOROURACIL/FOLINIC ACID FOR
TREATMENT OF PANCREATIC CANCER
Source text for Eikon: ID:nGNXOEZZFa
Further company coverage: XBIT.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke